Metabolism Research in Tumor-Associated Macrophages
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Immunology and Immunotherapy".
Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 2966
Special Issue Editor
Interests: macrophages; tumor microenvironment; MAPK; scaffold molecules; drug resistance; inflammation
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Tumor-associated macrophages (TAMs) are the major immune components of the tumor microenvironment (TME). A large body of scientific evidence indicates that TAMs play a crucial role in tumor development and progression. Clinical and animal model experiments have demonstrated that TAMs are associated with poor prognosis, drug resistance, enhanced angiogenesis, and metastasis in cancer. TAMs are a phenotypically diverse population of myeloid cells which display high plasticity and dynamic metabolic nature. Macrophages exhibit polarization into distinct phenotypic and functional subsets known as M1 and M2 macrophages in response to various activation stimuli. The dichotomy in M1 and M2 macrophages is also evident at the metabolic level. As metabolic reprogramming is recognized as a hallmark of cancers, a complete interpretation of pro-tumoral and anti-tumoral metabolic switch in TAMs is essential to understand the molecular mechanisms in cancer. It is becoming clear that the “immunosuppressive and protumoral” behavior of TAMs results from a rewired metabolic program which affects disease progression and outcome in cancer. However, the complexity and acquisition of a rewired metabolic program in tumor-associated macrophages is still only partially known. Understanding the contribution of multiple metabolic processes in TAMs regulated by the micro-environment could lead to the development of targeted agents and multi-targeting strategies to suppress cancer.
This Special Issue will highlight the current state of the art in tumor-associated macrophages metabolism, metabolic inhibitors, and future directions for pro-tumor macrophage reprogramming strategies.
Dr. Emanuele Giurisato
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Tumor-associated macrophages
- metabolic reprogramming
- macrophages targeted therapy
- tumor microenvironment
- M1-like and M2-like macrophages metabolism
- immunoregulation
- nitric oxide synthase
- glucose metabolism
- hypoxia
